Humira Drives Abbott’s Second Quarter Performance
This article was originally published in The Pink Sheet Daily
Executive Summary
With new Crohn’s indication, Humira sales jump 50 percent as firm’s pharma sales grow 17 percent.
You may also be interested in...
Abbott Submits Humira sBLA for Juvenile Rheumatoid Arthritis
If approved, Humira would compete directly with Wyeth/Amgen’s Enbrel in the indication.
Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.
IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.